Ann Clin Pharmacol Ther | Volume 1, Issue 1 | Research Article | Open Access
Dobrinov V1, Veselina Uzunova1, Tihomira Stoyanova1, Ani Georgieva2, Dobrin Svinarov3, Petar Petrov4, Martin Berger5, Albena Momchilova1, Reneta Toshkova2 and Rumiana Tzoneva1*
1Department of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Bulgaria
2Department of Experimental Morphology, Bulgarian Academy of Sciences, Bulgaria
3Department Clinical Laboratory & Clinical Pharmacology, University Hospital Alexandrovska, Bulgaria
4Department of Polymers, Bulgarian Academy of Sciences, Bulgaria
5German Cancer Research Center, Heidelberg, Germany
*Correspondance to: Rumiana Tzoneva
Fulltext PDFThe research is focused on the novel Cryogel Polycaprolactone (PCL)/Polyethylene Oxide (PEO) used as a drug carrier in anti-tumor therapy. Cryogels were prepared via the combination of cryogenic treatment and photochemical cross linking. HPLC was performed in order to study the kinetics of EPC3 release from the copolymers along with tandem-mass spectroscopy. The polymer drug delivery system loaded with Erufosine was transplanted into Graffi myeloid tumor in hamsters and biometric parameters such as lethality and mean survival time were monitored. The results showed that PCL/PEO cryogel implants release therapeutic doses of Erufosine by the controlled degradation of the polymers in vitro and in vivo. In vivo results demonstrate an increase of mean survival time and reduction of mortality of the animals with implanted postoperatively drug-loaded cryogels. All this results indicate that the PCL/PEO cryogels represent a promising drug-release system for the treatment of cancer.
Dobrinov V, Uzunova V, Stoyanova T, Georgieva A, Svinarov D, Petrov P, et al. Controled Release of Erufosine from New Cryogels Based on Polycaprolactone/Poly (Ethylene Oxide) Polymers and the Effect on Graffi Tumor-Bearing Hamsters. Ann Clin Pharmacol Ther. 2018; 1(1): 1004.